“Basilard BioTech’s non viral gene delivery technology platform (called Celletto – for use in the Cell & Gene Therapy industry) introduces the best, most scalable way to deliver cargo for genome engineering into individual human cells, by the hundreds of millions at a time. Celletto utilizes a nanomechanical, more precise approach to cell poration wherin each cell in suspension is captured (via microfluidic flow) in it’s own well on a silicon chip-based site capture array and then porated by a nano needle at the bottom of that well before being released via reverse flow.
The net result is uniform single incision mechanoporation of each cell (non stochastic and without rips and tears of the cellular membrane), consistent nuclear delivery (crucial for gene editing), massive parrallelization and rapid processing, simplified operation, better transfection performance and better cell viability.
Celletto is unique in that it is the only method akin to traditional microinjection – but scalable and with better performance. Unlike microinjection though, and most other approaches to non viral delivery, Celletto brings the “cell to the needle”. This innovation is a breakthrough that offers a real path to the ideal of scalable microinjection at clinically relevant throughputs in the hundreds of millions of cells per cycle.”
